Cogent Biosciences, Inc. (COGT)
NASDAQ:COGT
Want to see COGT full AI Analyst Report?
Top Page
Cogent Biosciences
(NASDAQ:COGT)
Select Model
Select Model
Rating:45Neutral
Price Target:
$34.00
▼(-8.72% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a balance sheet that still shows sizable equity. Technicals also detract due to a bearish trend (below key moving averages and negative MACD), despite oversold readings. Valuation contributes only modestly because a negative P/E provides limited insight and there is no dividend yield data.
Positive Factors
IND-enabling progress
Ongoing IND-enabling studies with an IND submission expected later this year represent a clear structural advancement from discovery toward clinical development. This milestone can materially de-risk the lead programs, enable human dosing, attract partnerships, and create multi-month to multi-quarter value inflection points tied to regulatory progress rather than short-term market moves.
Negative Factors
No commercial revenue
The absence of commercial revenue means the company is wholly dependent on capital markets or partnerships to fund operations. With no product-derived cash inflows, ongoing R&D and regulatory timelines must be financed externally, structurally increasing dilution risk and making long-term sustainability contingent on successful clinical/regulatory milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
IND-enabling progress
Ongoing IND-enabling studies with an IND submission expected later this year represent a clear structural advancement from discovery toward clinical development. This milestone can materially de-risk the lead programs, enable human dosing, attract partnerships, and create multi-month to multi-quarter value inflection points tied to regulatory progress rather than short-term market moves.
Read all positive factors
Cogent Biosciences (COGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.60B
Dividend YieldN/A
Average Volume (3M)1.78M
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth0.01%
CountryUS
Employees205
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume2,470,492
30 Day Avg. Volume1,775,120
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.71K
Enterprise Value/Ebitda-16.49
Forecast
1Y Price Target
$52.75Price Target Upside41.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$10.85M
Cogent Biosciences Business Overview & Revenue Model
Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mut...
How the Company Makes Money
null...
Cogent Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.49M | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -362.02M | -328.74M | -271.59M | -204.54M | -141.96M | -73.56M |
| Net Income | -354.30M | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
Balance Sheet | ||||||
| Total Assets | 903.01M | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M |
| Cash, Cash Equivalents and Short-Term Investments | 866.38M | 900.76M | 287.08M | 265.71M | 259.28M | 219.68M |
| Total Debt | 238.65M | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M |
| Total Liabilities | 295.31M | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M |
| Stockholders Equity | 607.69M | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M |
Cash Flow | ||||||
| Free Cash Flow | -286.27M | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M |
| Operating Cash Flow | -284.82M | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M |
| Investing Cash Flow | -505.36M | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M |
| Financing Cash Flow | 905.80M | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M |
Cogent Biosciences Technical Analysis
Negative
37.25
Price Trends
35.32
Negative
36.24
Negative
29.95
Positive
Market Momentum
-0.54
Negative
38.87
Neutral
43.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Negative. The current price of 37.25 is above the 20-day moving average (MA) of 33.73, above the 50-day MA of 35.32, and above the 200-day MA of 29.95, indicating a neutral trend. The MACD of -0.54 indicates Negative momentum. The RSI at 38.87 is Neutral, neither overbought nor oversold. The STOCH value of 43.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COGT.
Cogent Biosciences Risk Analysis
Cogent Biosciences disclosed 61 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cogent Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.79B | 12.75 | 17.19% | ― | 20.71% | -5.53% | |
62 Neutral | $2.98B | -46.92 | -5.89% | ― | 157.97% | 86.11% | |
61 Neutral | $1.50B | -77.26 | -4.83% | ― | 23.64% | -29.23% | |
58 Neutral | $2.45B | -17.99 | -13.96% | ― | 3118.14% | 55.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.60B | -11.21 | -36.95% | ― | ― | -68.57% | |
45 Neutral | $5.60B | -6.14 | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
COGT
Cogent Biosciences
32.26
26.62
471.99%
IDYA
IDEAYA Biosciences
28.40
7.30
34.60%
BEAM
Beam Therapeutics
29.55
12.40
72.30%
IRON
Disc Medicine
70.35
23.03
48.67%
HRMY
Harmony Biosciences Holdings
32.10
-3.06
-8.70%
IMCR
Immunocore Holdings
28.65
-9.05
-24.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.